	US 12,247,067 B2
	Antibody molecules and uses thereof
Neil Andrew Robert Gow, Aberdeen (GB); Fiona Marion Rudkin, Aberdeen (GB); Lars-Peter Erwig, Blunham (GB); and Allan Jensen, Frederiksberg (DK)
Assigned to THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, Aberdeen (GB)
Filed by THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, Aberdeen (GB)
Filed on Mar. 15, 2022, as Appl. No. 17/695,569.
Application 17/695,569 is a division of application No. 15/556,145, granted, now 11,306,138, previously published as PCT/GB2016/050577, filed on Mar. 4, 2016.
Claims priority of application No. 1503812 (GB), filed on Mar. 6, 2015.
Prior Publication US 2022/0204595 A1, Jun. 30, 2022
Int. Cl. C07K 16/14 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); G01N 33/569 (2006.01)

CPC C07K 16/14 (2013.01) [A61K 39/39575 (2013.01); A61K 45/06 (2013.01); G01N 33/56961 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01); G01N 2333/40 (2013.01); G01N 2469/10 (2013.01)]

8 Claims

1. A method of treatment of a Candida infection comprising administering an anti-Candida antibody molecule to an individual in need thereof, wherein the antibody molecule is a whole antibody comprising a VH domain comprising:

(i) a HCDR1 having the amino acid sequence of SEQ ID NO: 277;

(ii) a HCDR2 having the amino acid sequence of SEQ ID NO: 279; and

(iii) a HCDR3 having the amino acid sequence of SEQ ID NO: 281;

and a VL domain comprising:

(i) a LCDR1 having the amino acid sequence of SEQ ID NO: 284;

(ii) a LCDR2 having the amino acid sequence of SEQ ID NO: 286; and

(iii) a LCDR3 having the amino acid sequence of SEQ ID NO: 288.